Edition:
India

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

79.89USD
9:18pm IST
Change (% chg)

$-2.83 (-3.42%)
Prev Close
$82.72
Open
$82.41
Day's High
$82.43
Day's Low
$79.74
Volume
34,484
Avg. Vol
204,354
52-wk High
$84.23
52-wk Low
$41.68

Select another date:

Tue, May 8 2018

BRIEF-Ultragenyx Pharmaceutical Q1 Earnings Per Share $0.62

* ULTRAGENYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE

BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The U.S.

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE CRYSVITA® (BUROSUMAB-TWZA) NOW LAUNCHED IN THE U.S. FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA (XLH) IN CHILDREN AND ADULTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Ultragenyx Announces Filing And FDA Clearance Of An Investigational New Drug Application For DTX401

* ULTRAGENYX ANNOUNCES FILING AND FDA CLEARANCE OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR DTX401, A GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA

BRIEF-FDA Approves Ultragenyx Pharmaceutical's Crysvita To Treat An Inherited Form Of Rickets

* U.S. FDA SAYS APPROVED CRYSVITA (BUROSUMAB) TO TREAT ADULTS & CHILDREN AGES 1 YEAR & OLDER WITH X-LINKED HYPOPHOSPHATEMIA, AN INHERITED FORM OF RICKETS

FDA approves Ultragenyx's drug for rare form of rickets

The U.S. Food and Drug Administration has approved Ultragenyx Pharmaceutical Inc's treatment for a rare and inherited form of rickets, a condition that causes weak bones, the agency said on Tuesday.

FDA approves Ultragenyx's treatment for rare type of rickets

April 17 The U.S. Food and Drug Administration approved on Tuesday Ultragenyx Pharmaceutical Inc's treatment, Crysvita, for x-linked hypophosphatemia, a rare type of rickets.

BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301

* ULTRAGENYX ANNOUNCES POSITIVE TOPLINE RESULTS AND DMC REVIEW FROM FIRST COHORT OF PHASE 1/2 CLINICAL STUDY OF DTX301, AN INVESTIGATIONAL GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY

BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children

* KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN

BRIEF-Ultragenyx Reports Q4 Loss Per Share $1.89

* ULTRAGENYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE

BRIEF-Ultragenyx Prices Public Offering Of 4.39 Mln Common Shares At $57/Share

* ULTRAGENYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Select another date: